Amylin Combination Treatment Found Effective in Obesity Study
Posted on: Friday, 16 November 2007, 12:00 CST
Amylin Pharmaceuticals has announced positive results from a 24-week Phase IIa proof-of-concept study with pramlintide, an analog of human amylin, and metreleptin combination treatment in obese subjects.
At study end, pramlintide/metreleptin treatment reduced body weight on average by 12.7%, significantly more than treatment with pramlintide alone (8.4%). Subjects treated with pramlintide/metreleptin lost an average of 25 pounds from study start compared with an average of 17 pounds for subjects treated with pramlintide alone.
Subjects receiving pramlintide/metreleptin had continuous weight loss through the end of the study compared to those treated with pramlintide alone, whose weight loss had stabilized towards the end of the study. At study start, the average weight of study participants was approximately 205 pounds.
Alain Baron, senior vice president of research, Amylin, said: "We believe these important results provide convincing clinical proof-of-concept, highlighting the tremendous potential of our integrated neurohormonal strategy as a unique, innovative approach to obesity pharmacotherapy."
Source: Datamonitor
Related Articles
- Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
- Zelos Therapeutics Reaches Agreement With the FDA and EMEA for a Registration Study of ZT-031 for the Treatment of Osteoporosis
- BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
- First Twenty-Five Percent of Subjects in Phase 2 Melanoma Clinical Trial Treated
- Progenics and Wyeth Announce Positive Results From Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients With Advanced Illness
- VIVUS' Qnexa Phase 2 Study Results Demonstrate Significant Weight Loss, Reduction in Waist Circumference and Positive Effect on Factors Contributing to Metabolic Syndrome
- Arena Pharmaceuticals' Lorcaserin Hydrochloride Phase 2b Study Results Demonstrate Significant Weight Loss and Positive Effect on BMI and Waist and Hip Circumference in Obese Patients
- Shire Announces Positive Results of Two-Year Study of ADDERALL XR(R) in the Treatment of Adult ADHD
- Icagen Reports Results of Phase II Open Label Extension Study of ICA-17043 for the Treatment of Sickle Cell Anemia
- Multiple Studies at DDW Report on Adacolumn(R) Apheresis Device in Treating Inflammatory Bowel Disease
 |
 |
User Comments (0)
RSS Feeds